Modeling of New VHR Inhibitors Based on 4H-1,3,5-Oxadiazine Derivatives †
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Lominoga, E.R.; Zadorozhnii, P.V.; Hrek, O.O.; Kiselev, V.V.; Kharchenko, A.V. Modeling of New VHR Inhibitors Based on 4H-1,3,5-Oxadiazine Derivatives. Med. Sci. Forum 2022, 14, 64. https://doi.org/10.3390/ECMC2022-13144
Lominoga ER, Zadorozhnii PV, Hrek OO, Kiselev VV, Kharchenko AV. Modeling of New VHR Inhibitors Based on 4H-1,3,5-Oxadiazine Derivatives. Medical Sciences Forum. 2022; 14(1):64. https://doi.org/10.3390/ECMC2022-13144Chicago/Turabian Style
Lominoga, Elizaveta R., Pavlo V. Zadorozhnii, Olha O. Hrek, Vadym V. Kiselev, and Aleksandr V. Kharchenko. 2022. "Modeling of New VHR Inhibitors Based on 4H-1,3,5-Oxadiazine Derivatives" Medical Sciences Forum 14, no. 1: 64. https://doi.org/10.3390/ECMC2022-13144